Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
We sought to define the factors associated with the occurrence of stroke and systemic
embolism in a large, international atrial fibrillation (AF) trial.
[1
]
Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute,
PO Box 17969, Durham, NC 27710, USA. jonathan.piccini@duke.edu